Feasibility of decentralized real-world monitoring of SARS-CoV-2 booster vaccines and COVID-19 outcomes in myeloma

Authors

• William A Wood, University of North Carolina at Chapel Hill
• Mark A Schroeder, Washington University School of Medicine in St. Louis
• Ravi Vij, Washington University School of Medicine in St. Louis
• et al.

Journal

Blood Advances

Publication Date

5-12-2026

Volume

10

Issue

9

First Page

3094

Last Page

3102

Document Type

Open Access Publication

DOI

10.1182/bloodadvances.2025018963

Rights and Permissions

Wood WA, Kumar SK, Semmel EA, James S, Schroeder MA, Chung DJ, Rosenberg A, Zonder J, Rubinstein S, D'Souza A, Martin T, Chari A, Vij R, Nooka AK, Anderson KC, Neuberg DS, Richard S, Torres K, Weiss BM, Pederson L, Derkach A, Geyer S, Usmani SZ. Feasibility of decentralized real-world monitoring of SARS-CoV-2 booster vaccines and COVID-19 outcomes in myeloma. Blood Adv. 2026 May 12;10(9):3094-3102. doi: 10.1182/bloodadvances.2025018963. © 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Recommended Citation

Wood, William A; Schroeder, Mark A; Vij, Ravi; and et al., "Feasibility of decentralized real-world monitoring of SARS-CoV-2 booster vaccines and COVID-19 outcomes in myeloma." Blood Advances. 10, 9. 3094 - 3102. (2026).
https://digitalcommons.wustl.edu/oa_4/7467

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.